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Abstract 
Many studies have demonstrated that milk protein consumption has benefits in terms of promoting human health. 
This review assesses the intervention studies which have evaluated potential health enhancing effects in humans 
following the ingestion of milk proteins. The impact of milk protein ingestion has been studied to asses their 
satiating, hypotensive, antimicrobial, anti-inflammatory, anticancer, antioxidant, insulinotropic properties as well as 
their impact on morphological modifications (e.g., muscle and fat mass) in humans. Consistent health promoting 
effects appear to have been observed in certain instances (i.e., muscle protein synthesis, insulinotropic and 
hypotensive activity). However, controversial outcomes have also been reported (i.e., antimicrobial, anti-
inflammatory, anticancer and antioxidant properties). Several factors including interindividual differences, the 
timing of protein ingestion as well as the potency of the active components may explain these differences. In 
addition, processing conditions have been reported, in certain instances, to affect milk protein structure and therefore 
modify their bioactive potential. It is thought that the health promoting properties of milk proteins are linked to the 
release of bioactive peptides (BAPs) during gastrointestinal digestion. There is a need for further research to develop 
a more in-depth understanding on the possible mechanisms involved in the observed physiological effects. In 
addition, more carefully controlled and appropriately powered human intervention studies are required to 
demonstrate the health enhancing properties of milk proteins in humans. 
 
Key words: milk proteins; human studies; bioactive peptides; processing. 
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1. Introduction 1 
Milk proteins are recognized for their high nutritional quality. In addition, intact milk proteins 2 
have been associated with a wide range of in vitro bioactivities, such as satiating, antimicrobial, 3 
mineral binding, anti-lipidaemic and anticancer properties [2, 28, 30, 93]. During digestion in 4 
humans, milk proteins are cleaved by various proteinases and peptidases in the gastrointestinal 5 
tract (GIT), resulting in the generation of free amino acids and peptides [131]. Specific peptide 6 
fragments, also known as bioactive peptides (BAPs), have been shown in vitro to positively 7 
affect markers associated, for instance, with inflammation, hypertension, diabetes and 8 
osteoporosis [41, 52, 66, 96]. These BAPs may be released during gastrointestinal (GI) digestion 9 
of milk proteins in humans [15]. Several studies have reported that milk protein-derived BAPs 10 
may also play a beneficial in vivo role in humans [for reviews: see 7, 51, 84, 100]. 11 
To date, most studies in humans appear to have been conducted with hydrolysed milk proteins 12 
while intact milk proteins may also have some potential in human health [76]. Human 13 
intervention studies with intact milk proteins have focused on their satiating, hypotensive, 14 
antimicrobial, anti-inflammatory, anticancer, antioxidant and insulinotropic properties [44, 47, 15 
81, 102, 119, 130]. Milk protein consumption has also been shown to have potential in 16 
increasing muscle protein synthesis in humans [32, 135]. However, certain human intervention 17 
studies have failed to demonstrate health promoting effects following milk protein consumption 18 
[48, 103]. 19 
The aim of this review was to specifically investigate the potential link between milk protein 20 
consumption and their health promoting effects in humans. Therefore, human intervention 21 
studies which have been conducted with milk proteins were studied for a wide range of bioactive 22 
(i.e., satiating, hypotensive, antimicrobial, anti-inflammatory, anticancer, antioxidant and 23 
insulinotropic and muscle protein synthesis) properties. The outcomes of these human 24 
intervention studies as well as the parameters (e.g., dose, duration, health status of the subjects, 25 
etc.) which generally yielded health enhancement were studied. The scientific literature related to 26 
the bioactive properties of milk proteins in humans was assessed for the time period ranging 27 
from 1985 to 2015. Current evidence on the release of BAP sequences following milk protein 28 
ingestion in humans was collated. The impact of processing on milk protein structure and the 29 
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effect on the bioactivity was also assessed to better understand how these may modulate peptide 30 
release and in turn impact on human health. 31 
2. Satiating and weight management effects of milk proteins in 32 
humans 33 
It has been suggested that a significant increase in protein intake, over habitual intake, could help 34 
in weight management and positively alter body composition [2, 77, 128]. Significant differences 35 
in anthropometric parameters were reported in healthy and obese humans when the protein 36 
concentration in the test group was on average 58.4% (g/kg/day) higher than in the control 37 
group. In contrast, no effect on food intake was observed with differences of up to 38.8% 38 
(g/kg/day) between the test and control groups [14]. Milk proteins, which have been described 39 
for their satiating properties, may have potential for use as natural dietary components to reduce 40 
food intake in humans [2, 36, 77, 115, 128]. Numerous human intervention studies have focused 41 
on the satiating properties of milk proteins and their effect on the reduction of food intake [for 42 
reviews: see 13, 77]. A strong link between protein intake and weight loss has been suggested, 43 
highlighting the role of their texturizing properties, amino acid composition and rate of 44 
absorption in increasing satiety. However, to date, a direct link between satiety and food intake 45 
reduction followed by weight loss has proved difficult to establish in humans. 46 
Owing to differences between the rate of digestion, amino acid and peptide appearance in the 47 
plasma, whey proteins (WPs) have been postulated as being more satiating than caseins (CNs). A 48 
faster gastric emptying for WPs compared to CNs has been shown [2]. Differences were found 49 
with intact CN solutions, which showed a slower rate of intestinal absorption compared to the 50 
WPs [22]. This was linked to the fact that part of the CN may coagulate at the acidic gastric pH, 51 
thereby delaying CN protein breakdown [56]. On a time scale basis, it has been suggested that 52 
WPs are more satiating in the short term and CN in the long term [13]. 53 
Table 1 summarizes the outcomes of human intervention studies conducted with intact milk 54 
proteins. A positive role of WPs in reducing food intake has been shown in human studies 55 
involving obese subjects [9, 122]. Recently, a 12 week study was conducted with obese subjects 56 
with a body mass index (BMI) between 25 and 40 kg m
-2
 who received a preload of whey protein 57 
concentrate (WPC, 65 g) before an ad libitum meal [122]. At the end of the intervention, there 58 
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was a significant effect of the WPC preload on appetite (-41%), calorie intake (-50%), 59 
anthropometry (reduction in body weight and waist circumference) and body composition 60 
(reduction in fat and increase in lean muscle mass) relative to the baseline. A 23 week. 61 
intervention with WPs carried out with obese subjects showed the same outcomes with a 62 
reduction in weight (-2.5%), fat mass (-2.3 kg), waist circumference (-2.4 cm) and fasting ghrelin 63 
(-13.6%) compared to a control group receiving an isocaloric maltodextrin drink [9]. In contrast, 64 
with overweight adolescents, the intake of skimmed milk, CN and WP (30 [72] or 35 g/day [6]) 65 
over 12 weeks was shown to negatively affect anthropometric parameters. The 3 milk proteins 66 
caused an increase in BMI, BMI-for-age Z-scores and weight. Fasting insulin, homeostatic 67 
model assessment (HOMA, a predictor of insulin resistance) and fasting C-peptide (a surrogate 68 
marker of insulin resistance) increased in the WP and CN groups compared to baseline. 69 
However, these changes were not seen in the control group receiving water instead of the milk 70 
protein drinks [6]. A significant increase in lean and fat mass was seen with the 3 milk proteins. 71 
In addition, there was a 30 and 15% increase in leptin (an orexigenic hormone) levels in the CN 72 
and WP groups, respectively. In contrast, consumption of water instead of the milk proteins 73 
resulted in a significant increase in lean mass but not in fat mass. These studies suggested that in 74 
obese adolescents, water intake instead of milk protein drinks may be more beneficial to 75 
positively alter body composition [6, 72]. 76 
-Lactalbumin (-La) is rich in Trp, the precursor of serotonin, which has been linked to 77 
cognitive function and in certain instances to satiating effects in humans [for review, see: 99]. -78 
La has been shown to increase free plasma Trp in humans, which may have resulted in an 79 
increase in hypothalamic serotonin [83]. Supplementation of -La in a custard-style breakfast 80 
reduced subsequent energy intake by 20% in an ad libitum lunch in healthy humans with a BMI 81 
between 22 and 32 kg m
-2
 [130]. The reduction in food intake was directly correlated with a 82 
reduction in appetite (-40%). This effect was not observed with other milk proteins including 83 
CN, whey, and whey with caseinomacropeptide (CMP) [130]. Similarly, with other milk 84 
proteins, no significant differences in energy intake and lean body mass were seen. No 85 
subsequent reduction in food intake was found with 18 lean subjects ingesting a preload of 86 
different WP ingredients (25 g of WPC, CMP, -lactoglobulin (-Lg) or colostrum WPC) 90 87 
min before an ad libitum lunch [111]. However, -Lg induced a greater feeling of subjective 88 
fullness. Different WPs (whey protein isolate (WPI), whey without CMP and CMP isolate) were 89 
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consumed as a preload (25 g) 75 min before an ad libitum lunch [21]. The CMP preload induced 90 
a higher pre-meal subjective satiety and a lower compensatory food intake on the study day. 91 
However, these effects, which were linked with a higher cholecystokinin (CCK) release, were 92 
only seen within the female and not the male group. Similarly, the consumption of CMP and 93 
WPI with a high and low CMP content as a preload (60 g) drink 120 min before an ad libitum 94 
lunch was studied with 22 healthy females with a BMI of 20-25 kg m-2. Only the WPIs induced a 95 
reduction in food intake by more than 15% in comparison to CMP [27]. 96 
In the context of exercise, milk proteins have been described for their positive role as recovery 97 
drinks in humans [61]. Reduction of caloric intake (-25.2%) has been shown post-exercise (30 98 
min cycling) in females following the consumption of skim milk (600 mL) vs. orange juice drink 99 
[115]. Similarly, anthropometric modifications (increased lean mass and decreased fat mass) 100 
were reported while combining exercise and fat free milk consumption in male (500 mL for 12 101 
weeks [49] and female (1000 mL for 12 weeks) [58] subjects. 102 
While food protein digestion is affected by its structure, several studies have not taken into 103 
consideration the impact of the food structure on food satiety eventhough it is known to be an 104 
important component in satiety. An effect of food structure (liquid milk vs. yoghurt) in delaying 105 
gastric emptying in humans has been reported [45, 79]. It has been proposed that food structure 106 
may play a greater role in satiety than the protein type itself [60]. For example, modification of 107 
CN by enzymatic cross-linking with transglutaminase (EC 2.3.2.13) increased the feeling of 108 
fullness and induced a lower postprandial glucose response along with lower insulin and CCK 109 
concentrations in healthy humans [60]. These effects were explained by the differential 110 
accessibility of the enzymes to the CN proteins, which affected the kinetics of release of free 111 
amino acids and peptides in the GIT and in the circulation. 112 
In summary, the effect of milk proteins on satiety has not been consistently demonstrated in 113 
humans. However, several studies appear to indicate that milk protein administered as a preload 114 
positively affect subjective satiety. This effect seems to be protein dependent, with selected WPs 115 
(i.e., -La and -Lg) generally having a greater impact than CN. Sex also appeared to affect the 116 
response to milk protein ingestion, which is possibly linked to hormonal differences between 117 
males and females. There did not appear to be a link between subjective satiety and a reduction 118 
of food intake in humans as in many instances, satiety ratings did not translate into a reduction in 119 
food intake. Milk proteins were shown to have an impact on food intake when consumed in 120 
 7 
 
amounts  20 g as a meal preload both in healthy and overweight/obese adults. Morphological 121 
changes, including a reduction in weight, fat mass and an increase in lean mass were reported in 122 
obese subjects consuming milk proteins ( 50 g/day) for periods  12 weeks. In contrast, in 123 
obese adolescents, the opposite was reported with a negative effect of milk protein intake ( 30 124 
g/day) on BMI. Overall, the inclusion of milk proteins in the diet may be used as an alternative to 125 
reduce weight and improve body composition of adults. However, with overweight/obese 126 
adolescents, the opposite strategy consisting in no further supplementation of the diet with milk 127 
proteins may be suggested. 128 
3. Hypotensive properties in humans following the ingestion of milk 129 
proteins 130 
A link between the consumption of dairy products and a reduced risk of heart diseases has been 131 
suggested in several human intervention studies [for review, see: 46]. Following the intake of a 132 
WPC80 (28 g/day) beverage for 6 weeks, a significant reduction of diastolic blood pressure 133 
(DBP; -8.6 mm Hg) and systolic blood pressure (SBP; -8.0 mm Hg) were reported in stage 1 pre-134 
hypertensive young adults. In contrast, no effects of the WPC80 on blood pressure (BP) were 135 
reported in healthy young adults [42]. Consumption of 2  27 g WPI and CN administered daily 136 
over 12 weeks was shown to induce a reduction in SBP (-4%) and DBP (-3%) compared to the 137 
control group [102]. The augmentation index (AI) decreased by 14% for WP and was not 138 
significantly modified by CN intake. Interestingly, it has been shown that the hypotensive effects 139 
were not linked with serum ACE inhibition [102]. However, ACE has been identified in the 140 
gastrointestinal tract of humans [19, 38]. Therefore, it is likely that direct effects at the GIT level 141 
may be involved in the hypotensive activity seen following milk protein intake in humans. 142 
Supplementation of WP and CN (30 g/day for 4 weeks) to obese females combined with 143 
resistance exercise was shown to have a positive effect on reducing BP. At the end of the 144 
intervention, there was a significant reduction in SBP (-7 and -6 mm Hg for WP and CN, 145 
respectively) and AI (-34 and -31% for WP and CN, respectively). In addition, it was 146 
demonstrated for the first time that arterial stiffness measured by brachial-ankle pulse wave 147 
velocity could be significantly reduced (-4 cm s
-1
 in both groups) by ingestion of intact WP and 148 
CN. In contrast, DBP was not modified compared to baseline [40]. 149 
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To date, most studies which have investigated the effects of milk protein intake on hypertension 150 
have been conducted in adults. The effect of skim milk, WP or CN (35 g/day for 12 weeks) 151 
intake on BP has recently been investigated in obese adolescents [5]. No effect on SBP and 152 
arterial stiffness could be seen at the end of the dietary intervention. However, reductions in DBP 153 
of -1.8 and -2.2 mm Hg in the CN and the control group, respectively, were reported. 154 
The hypotensive effects reported in certain studies may be linked to the release of angiotensin 155 
converting enzyme (ACE) inhibitory peptides in the GIT of humans following the ingestion of 156 
milk proteins (Table 2). In summary, dietary intervention studies with milk proteins have only 157 
shown a modest reduction in SBP and DBP or no effect. The largest effect seen (-8.6 and -8.0 158 
mm Hg in DBP and SBP, respectively) was observed with pre-hypertensive subjects who 159 
received 28 g WPC80/day for 6 weeks. These effects may be similar to those previously seen 160 
with ACE inhibitory lactotripeptides (LTPs – i.e., Ile-Pro-Pro and Val-Pro-Pro), also reporting 161 
higher hypotensive effects in human subjects having a higher basal BP [for reviews, see: 39, 162 
100]. 163 
4. Antimicrobial role of milk proteins in humans 164 
Particular attention has to date been given to lactoferrin (LF), a minor WP, as it is able in its 165 
intact format to display antimicrobial activities. The mechanisms involved are thought to relate 166 
to binding to the lipopolysaccharide membrane of microorganisms. LF has been shown to induce 167 
membrane disruption, to penetrate into dendritic cells, to sequester iron and to display prebiotic 168 
activities preventing pathogen growth [17, 24, 50, 90, 118, 123]. 169 
Several human studies are found in the literature evaluating the antimicrobial properties of intact 170 
LF [104]. A human recombinant LF solution (600 mL at 5 mg mL
-1
) was administered via 171 
gastrostomy tubes for 56 days to nursing-home residents at the start of an antibiotic treatment 172 
[70]. This resulted in a decreased incidence of antibiotic-associated diarrhea, which has in certain 173 
instances been linked with the presence of Clostridium difficile. Diarrhea was seen with 44% of 174 
the subjects receiving the LF solution as opposed to 92% in the control group administered with 175 
a placebo. Bovine LF has also been used as an adjunct in the triple therapy against Helicobacter 176 
pylori in randomized control trials (RCTs) [33, 34]. There was a higher rate of H. pylori 177 
eradication in the group receiving the clarithromycin/tinidazole/rabeprazole 7 day triple therapy 178 
combined with bovine LF (92.2 [34] and 90% [33] H. pylori eradication) than in the group 179 
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receiving the triple therapy alone (71.2 [34] and 77% [33] H. pylori eradication). The positive 180 
effect of LF may be antibiotic specific as no additional benefit of bovine LF on H. pylori 181 
eradication was seen in another study using an esomeprazole/clarithromycin/amoxicillin 7 day 182 
triple therapy [140]. In addition, human recombinant LF (250 or 1 000 mg doses, 5 times over a 183 
24 h period) when ingested on its own did not allow eradication of H. pylori in 12 healthy 184 
subjects infected with the bacteria [101]. Similar results were reported, also showing no effect of 185 
human recombinant LF administration (1 000 mg, 5 times for 5 or 14 days) on H. pylori in 186 
humans [48]. Consumption of fermented milk has been linked with a reduction in H. pylori 187 
infection in humans. However, this effect may arise from the contribution of different factors 188 
including other milk components, BAPs and probiotic organisms [117]. 189 
The beneficial role of bovine LF in delaying the onset of late-sepsis in very low-birth-weight 190 
(VLBW) neonates has also been evaluated in different studies. The frequency of occurrence of 191 
bacterial and fungal late-onset of sepsis was decreased from 17.3% in the control group fed with 192 
a placebo to 5.9% in the test group receiving LF (100 mg/day until age 30 days) [81]. Similarly, 193 
a reduction in the incidence of fungal infection (0.7 and 7.7% for the LF and control group, 194 
respectively [82]) and necrotizing enterocolitis (NEC, 2.0 and 5.4% for the LF and control group, 195 
respectively [80]) were also seen in VLBW neonates and infants. 196 
Overall, the antimicrobial effects following milk protein ingestion appear to mainly arise from 197 
LF. While several studies have concluded in a positive effect of LF in controlling conditions 198 
associated with human infections (e.g., diarrhea), the use of LF on its own has not been shown to 199 
correlate with a complete removal of pathogens in various human intervention studies. The 200 
combination of LF with other agents such as antibiotics or probiotics, however, seems to yield 201 
promising results in several instances (NEC and H. pylori). Co-ingestion of quantities as low as 202 
100 mg LF over 7 days were shown to enhance antimicrobial activity. These results suggest that 203 
milk proteins have potential as adjuncts to antimicrobial drugs and other natural alternatives. 204 
5. Anti-inflammatory effects of milk proteins in humans 205 
Studies have demonstrated a post-prandial reduction in low-grade inflammatory biomarkers 206 
(monocyte chemotactic protein-1 (MCP-1) and CC chemokine ligand-5 regulated on activation 207 
in normal T cell expressed and secreted (CCL5/RANTES), a biomarker of atherosclerosis) in 208 
obese non-diabetic human subjects following the consumption of CN and particularly WPs [53]. 209 
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After consumption of a high fat meal and 45 g (on a protein basis) of WPI, a decrease in 210 
CCL5/RANTES (36% below the baseline) was seen [53]. Contradictory results are also found in 211 
the literature showing that WPI or caseinate intake (45 g at breakfast over 3 weeks) in post-212 
menopausal overweight women had no effect on inflammatory markers, i.e., C-reactive protein 213 
(CRP), IL-6 and tumor necrosis factor (TNF)-α [103]. Similar results were reported during an 214 
intervention study with 27  2 g daily of WPI or caseinate at breakfast for 12 weeks in 215 
obese/overweight individuals [102]. 216 
Interestingly, several immunomodulatory peptides such as -casomorphin 7 (-CN (f 603-66)) 217 
have been identified in the GIT of humans following milk protein intake (Table 2). Therefore, 218 
these may have potential to act at least at the gut level as anti-inflammatory/immunomodulatory 219 
agents. To date, the anti-inflammatory properties of milk proteins appear to have mainly been 220 
studied in the context of obesity in humans. Overall, the results on the anti-inflammatory 221 
properties in humans caused by the ingestion intact milk proteins appear to be inconclusive. 222 
While some effects were reported in a post-prandial study on markers of low-grade 223 
inflammation, others studies have failed in demonstrating a benefit of milk protein consumption 224 
on the inflammatory status of overweight subjects. 225 
6. Anticancer effects of milk proteins in humans 226 
The majority of studies demonstrating the anticancer activity of milk proteins appear to have 227 
been carried out with LF. In the context of colorectal cancer, for example, a study was conducted 228 
in 104 participants (40-75 y) with polyps ≤ 5 mm diameter [67]. Bovine LF was supplemented 229 
for a 12 month period at a daily intake of 1.5 (60.25) or 3 (60.5) g. Overall, there was no 230 
significant effect of LF on polyp growth. However, the 3 g bovine LF intake significantly 231 
retarded colorectal adenomatous polyp growth in subjects  63 y, with a higher effect being 232 
observed in females than in males. The mechanisms of action are not yet understood, but they 233 
may involve immunomodulatory effects, an increase in human plasma LF concentration (causing 234 
a reduced infiltration of polymorphonuclear leukocytes in the polyps) and possibly the iron 235 
chelating activities of LF at the polyp sites [67]. A second study was recently conducted with 236 
colorectal cancer patients undergoing chemotherapy who were supplemented with 250 mg/day 237 
bovine LF for 3 months [87]. The effects seen with bovine LF supplementation were not 238 
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significantly different from the control, with the exception of an increased anti-inflammatory and 239 
immunomodulatory effect. In addition, several side-effects (liver and kidney toxicity and 240 
mucositis) associated with the chemotherapy were alleviated in the bovine LF treated group and 241 
certain symptoms such as anemia were decreased [87]. 242 
Complexes of the Ca-depleted apo form of -La in the molten globule state stabilized by a fatty 243 
acid cofactor (oleic acid), named human (or bovine) -La made lethal to tumors (HAMLET/ 244 
BAMLET), have been reported for their antitumor properties. A small number of human studies 245 
have been conducted to demonstrate the antitumor activity of HAMLET [43]. Following a 3 246 
week application of HAMLET (0.7 mM in 0.9% saline on each lesion) to skin papillomas, a 247 
reduction in lesion volume by  75% was seen in the test group (20 subjects). A complete 248 
resorption of the lesions was reported after treatment and the subjects remained free of lesions 249 
after a 2 y follow-up [47]. A positive effect of HAMLET in 9 bladder cancer patients has also 250 
been demonstrated. HAMLET was instilled (5  25 mg mL-1) daily in the bladder for 5 days. 251 
Tumor cell apoptosis together with a reduction in tumor size and a change in tumor character 252 
such as surface atrophy were observed [92]. 253 
Two peptides sequences (Val-Glu-Asn-Leu-His-Leu-Pro-Leu-Pro-Leu-Leu and Asn-Leu-His-254 
Leu-Pro-Leu-Pro-Leu-Leu, -CN (f 130-140) and -CN (f 132-140), respectively) previously 255 
reported for their anticancer activity in cell cultures [59] have been found in the jejunum of 256 
humans following milk protein ingestion (Table 2). While their in vivo effects are unknown, they 257 
may be relevant to gut related cancers. In summary, utilization of a dietary strategy to 258 
prevent/manage cancer is very interesting, given the deleterious side-effects of chemotherapy for 259 
cancer patients. Milk proteins and particularly LF and HAMLET have shown various positive 260 
effects on the resorption of lesions/polyps, or cancerous cell development (e.g., apoptosis). 261 
Furthermore, results showing the alleviation of chemotherapy side-effects or a reduction of 262 
inflammatory markers were reported. These effects could be seen at relatively low LF doses < 3 263 
g daily. While milk proteins cannot replace drugs in cancer treatment, the current scientific 264 
evidence suggests that they may be utilized to complement anticancer drugs as well as reducing 265 
their side-effects in humans. In addition, the role of HAMLET as a carrier of anticarcinogenous 266 
agents may be further investigated to improve possible synergies between milk proteins and 267 
drugs in the management of cancer. 268 
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7. Antioxidant effects of milk proteins in humans 269 
Antioxidant species (such as reactive nitrogen and oxygen species (ROS)) are naturally found 270 
within the human body. However, high levels of antioxidant species are detrimental to human 271 
health as they may lead to cell damage [109]. The ingestion of milk proteins by humans has, in 272 
certain instances, been reported to reduce oxidative stress. Supplementation of healthy males 273 
participating in a resistance training program with WPI induced a significant increase in plasma 274 
total antioxidant capacity (TAC; +4%) and glutathione (GSH; +12%) level [119]. It was 275 
suggested that combining resistance training with WP consumption could help reduce the 276 
oxidant status in humans [119]. However, a different trend was reported in a similar study where 277 
WP supplementation combined with resistance training did not decrease the oxidant status in 278 
humans [18]. The impact of a Cys-rich WPI (20 g daily for 12 weeks) on plasma oxidative status 279 
(GSH and TAC) was evaluated in subjects with non-alcoholic steatohepatitis [26]. Along with an 280 
average weight reduction and other physiological improvements, the treatment led to an 281 
increased plasma TAC (+61%) and GSH (+28%) levels [26]. 282 
Interestingly, a CN-derived peptide (Val-Leu-Pro-Val-Pro-Gln-Lys, -CN (f 170-176)) with in 283 
vitro antioxidant properties has been identified in the jejunum of humans following the digestion 284 
on milk proteins (Table 2). The possible role of this peptide in humans is still unknown. In 285 
summary, the effect of milk proteins on reducing oxidative status in humans is still unclear based 286 
on the scientific evidence to date. The antioxidant effects which have been reported in humans 287 
following dietary intervention with milk proteins are quite modest. There does not seem to be a 288 
clear scientific basis to recommend an increase of intact milk protein intake as a means of 289 
decreasing oxidative status in humans following exercise. The positive effect reported in the 290 
Cys-rich WPI is likely due to the Cys residue which is a well-known antioxidant amino acid and 291 
also a GSH building block. 292 
8. Insulin secretory and serum glucose regulatory role of milk 293 
proteins in humans 294 
Consumption of milk proteins has been linked with serum glucose regulatory properties in 295 
humans [for review: see 105]. In acute human studies, it was suggested that WPs had a higher 296 
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insulinotropic activity than CN, owing to their faster rate of digestion [94, 95]. However, in 297 
certain studies conducted with type 2 diabetic subjects, no significant differences between WP 298 
and CN ingestion were evidenced on insulin secretion and serum glucose levels [91]. 299 
WPs (55 g) ingestion 30 min before or during a high carbohydrate meal by type 2 diabetic 300 
subjects led to an increase in insulin secretion and a reduction in glycaemia [78]. Other studies 301 
also showed that supplementation of a high carbohydrate lunch with 27.6 [44] and 50 g [57] WPs 302 
induced insulinotropic effects and a post-prandial reduction in serum glucose in type 2 diabetics. 303 
Similar results were reported following the consumption of WPC administered 30 min before a 304 
meal, yielding a reduction of post meal blood glucose and insulin levels in a dose-dependent 305 
manner in healthy young adults [1]. The blood glucose regulatory effects of WPs were explained 306 
by a faster gastric emptying in the presence of WPs, which had incretin (glucagon like peptide-1 307 
(GLP-1), CCK and glucose inhibitory polypeptide (GIP)) secretagogue activities [1, 44, 57, 64, 308 
78]. The increase in plasma concentration of specific amino acids, including Leu, Ile, Thr, Val, 309 
Phe, Arg and Lys, and possibly peptides, which are thought to act as insulin secretagogues, has 310 
also been reported to correlate with the insulinotropic/hypoglycaemic activity of milk proteins 311 
[23, 89, 94, 95]. Other mechanisms of action may include inhibition of the activity of different 312 
metabolic enzymes also involved in the regulation of serum glucose such as dipeptidyl peptidase 313 
IV (DPP-IV) and -glucosidase [68, 97]. However, in a recent study [57], plasma DPP-IV 314 
activity was measured in the post-prandial phase with (test group) or without (placebo) a WP 315 
preload (50 g) [57]. No significant effect of WP was seen eventhough higher levels of active 316 
GLP-1 were observed in the test compared to the placebo group. 317 
While other studies have evaluated the role of intact milk proteins on insulin secretion and blood 318 
glucose regulation, it has been suggested that hydrolysed proteins generally display higher 319 
insulinotropic effects than unhydrolysed proteins [23, 89, 112]. This effect was attributed to a 320 
greater increase in plasma amino acids and di-peptides seen with pre-hydrolysed milk proteins 321 
[64, 89, 127]. 322 
To sum up, in several instances, the consumption of milk proteins and more particularly WPs has 323 
been linked to improved serum glucose regulation (higher insulinemia and lower glycaemia) in 324 
the post-prandial phase. The effects were acute and could be observed in healthy and type 2 325 
diabetic subjects with doses as low as 10 and 28 g milk proteins, respectively. In a few instances, 326 
positive effects of WP preload on the level of incretin hormones have been demonstrated. Within 327 
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the peptides which have been identified in the gastrointestinal tract of humans subsequent to milk 328 
protein digestion, a number of the peptide fragments have previously been reported to possess 329 
DPP-IV inhibitory activity (Table 2). Although no human study appears to have linked milk 330 
protein ingestion to DPP-IV inhibition, it may be possible that DPP-IV inhibition occurs directly 331 
in the gastro-intestinal tract. This could in part explain the incretin effect observed in dietary 332 
intervention studies with milk proteins and therefore their insulinotropic activity. 333 
9. Muscle protein synthesis action of milk proteins in humans 334 
It is well accepted that athletes have a higher requirement for dietary proteins than sedentary 335 
individuals. Milk proteins have been used as ingredients in the formulation of sport nutrition 336 
products for their positive role in myofibrillar protein synthesis (MPS) [135]. MPS, will in turn, 337 
repair damaged muscle proteins, maintain lean mass and induce muscle hypertrophy. The timing 338 
of protein ingestion after exercise is thought to be important as a “window of opportunity” (or 339 
anabolic window) during which MPS is optimum has been suggested [107]. However, recent 340 
studies suggest that the quality/amount of the protein rather than the timing is the important 341 
determinant in MPS following exercise [for review, see: 8]. The digestibility and high level of 342 
branched chain amino acids (BCAA) in WPs, and particularly Leu, confer them with a good 343 
nutritional profile for sports nutrition [107, 110, 124]. In addition to building up muscle mass, 344 
oxidative status is another parameter which athletes aim to control in order to improve 345 
performances. Antioxidant status is compromised during physical exercise due to an increase in 346 
the respiratory metabolism which yields an increase in ROS in muscle (see section 7). The 347 
increase in ROS can result in an inflammatory reaction in muscle which is generally manifested 348 
by an increase in phagocytes in muscle following physical exercise [4]. This increase in 349 
oxidative and inflammatory status can have adverse effects as it may lead to increased fatigue 350 
during exercise. 351 
The consumption of milk proteins (CN and WPs) associated or not with resistance training has 352 
been shown to correlate with an increase in MPS in young adults [114, 124, 125]. MPS is also 353 
highly relevant to the elderly population. Elderly people sometimes face malnutrition or 354 
undernutrition issues which may cause several complications including sarcopenia. Sarcopenia is 355 
defined as the loss of skeletal muscle mass. Sarcopenia may result in a reduction in mobility, and 356 
in certain instances in elevated fracture risk [16]. It is thought that in the elderly population, an 357 
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“anabolic resistance” following protein ingestion may prevail, which is characterized by less 358 
efficient muscle protein synthesis [62, 88]. An increased protein intake combined with an 359 
exercise regimen may help increase MPS and decrease body fat in elderly people [29, 32, 106]. 360 
Differences between WPs and CN have been found for post-prandial MPS. MPS was higher 361 
(+60%) following WPs than CN intake [20]. This was linked with the faster digestion of WPs 362 
compared to CN, resulting in higher levels of free amino acids in the circulation [31]. 363 
Furthermore, a Leu threshold, which corresponds to an intake of 2 g Leu, has been suggested as a 364 
rate limiting step in MPS, which may explain the development of sarcopenia in the elderly 365 
population [133, 136]. Therefore, Leu fortification in foods has been suggested as a means to 366 
increase MPS in the elderly population [133]. 367 
In summary, a positive role of milk proteins and more particularly WPs on MPS appear to have 368 
been consistently reported in human intervention studies at doses  20 and  7 g in healthy adults 369 
and elderly subjects, respectively. These effects were seen in acute studies and were enhanced in 370 
the context of an exercise regime. Milk proteins, notably WPs show promise for muscle repair 371 
and synthesis in the context of sports and elderly nutrition. 372 
10. Influence of food processing on the release of bioactive peptides 373 
Various technological processes may be applied to milk proteins which can affect their bioactive 374 
properties. These processes include enzymatic hydrolysis, fermentation, thermal and pressure 375 
treatments. Processing treatments such as enzymatic hydrolysis of milk proteins can affect their 376 
susceptibility to subsequent digestion. The impact of enzymatic hydrolysis on the bioactive 377 
properties of milk proteins in humans has recently been reviewed by Nongonierma and 378 
FitzGerald [100]. Therefore, this section will mainly deal with the possible effects of thermal and 379 
pressure treatments on the digestibility of milk proteins. 380 
Thermal treatment is often applied to milk, which can result in alteration of the conformation of 381 
milk proteins which subsequently affect their digestibility [121]. Heat-treatment of milk proteins 382 
has been shown to positively affect the susceptibility of -Lg to in vitro and in vivo (rat pup 383 
model) digestion with pepsin [65, 132]. This may be linked to modifications in -Lg 384 
conformation (disulfide bond cleavage and Maillard reaction) following heat-treatment [65, 113, 385 
132]. Although protein digestion is facilitated following heat-treatment, Wada and Lönnerdal 386 
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[132] have shown that specific peptide bonds could not be cleaved. This was linked to the 387 
formation of Amadori products such as lactulosyllysine and cross-linked products (lysinoalanine, 388 
lanthionine and aggregates via disulfide bonds), which could not be recognized by digestive 389 
enzymes [132]. When CN and WPs are present in the same sample, ultra-high temperature 390 
(UHT) treatment may result in an increase in the interactions between CN micelles and WPs. 391 
This results in a weakening of the CN micelle structure and the appearance of aggregates, often 392 
increasing accessibility of the proteins to digestive enzymes in humans [69]. 393 
Application of high pressure treatments can induce milk protein denaturation, causing structural 394 
modifications of both CN and WPs [3, 10, 54, 63, 116, 134]. The effects of high pressure 395 
treatment on WPs have recently been reviewed by Piccolomini, Kubow and Lands [108]. The 396 
impact of high pressure treatments on milk protein digestibility has mainly been studied using 397 
SGID protocols [37, 55, 129, 138, 139]. However, a few human intervention studies have been 398 
conducted with high pressured milk proteins. For instance, the higher GSH lymphocyte 399 
concentration (+24%) seen in humans following the consumption of pressurized WPI (45 g/day 400 
for 2 weeks) has been linked with increased WPI digestibility and possibly a higher 401 
bioavailability of Cys [137]. In contrast, no effects of pressurized WPI on blood GSH were 402 
found in cystic fibrosis [71] or chronic obstructive pulmonary disease (COPD) sufferers [73]. 403 
Animal models have been used to better understand the impact of milk protein processing on the 404 
release of peptides during digestion [11, 12]. A trial with 18 month old mini-pigs fed with raw or 405 
heated (90C for 10 min) milk, having similar compositions but different structures (liquid vs. 406 
rennet gel) was conducted [12]. Thermal treatment resulted in a faster digestion of milk proteins 407 
in contrast with gelation which slowed down gastric emptying and the rate of milk protein 408 
digestion [12]. In addition, identification of peptides released following the digestion of milk 409 
protein-based products was carried out in 18 month old mini-pigs [11]. The digestion of milk 410 
protein-based products with similar compositions but different structures (liquid milk, acid and 411 
rennet gels) prepared from raw or heated (90C for 10 min) milk was studied. Sampling of the 412 
digesta was conducted in the duodenum to specifically study peptide release between gastric 413 
digestion and intestinal absorption. This allowed identification of a wide range of peptides (16 414 
000) which originated principally from the four CNs (s1-, s2-, - and -CN) and -Lg. For 29 415 
of the peptides identified, in vitro bioactive properties including ACE inhibitory, anti-thrombotic, 416 
antimicrobial, anti-stress, antioxidant, opioid agonist, immunomodulating, protease/peptidase-417 
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inhibitory and mineral-binding properties had previously been reported in the literature. It was 418 
shown that both the pH and matrix structure affected the kinetics of peptide release. Acid gels 419 
were digested more rapidly than liquid milk, followed by rennet gels. The effect of pH was 420 
explained by the fact that acid gels had a pH value closer to that of the optimum pH for pepsin 421 
(2.0) while liquid milk may have slowed down pepsin activity through its buffering capacity. In 422 
the case of rennet gels, their compact structure may have limited the access of digestive enzymes 423 
[11]. 424 
It is generally accepted that the structure of milk proteins affects their digestibility in humans 425 
[45, 79, 126]. In particular, the rate of nitrogen release from whey products has been reported to 426 
be faster than that of CN due to differences in the gastric emptying for both proteins. However, 427 
this is only observed with micellar CN as processed CN has lost its ability to form micelles 428 
[126]. The effect of the dairy matrix structure on the kinetics of digestion has recently been 429 
studied in a model of gastric emptying [74]. The kinetics of digestion was shown to be mostly 430 
influenced by the rate of gastric emptying, which was governed by the matrix structure. To our 431 
knowledge, there are a limited number of studies available in the scientific literature which have 432 
directly addressed the impact of food structure following processing on the kinetics of peptide 433 
release in the GIT of humans. The impact of liquid milk heat treatment (pasteurization and UHT 434 
processing) vs. no heat treatment (microfiltration) on digestion has been evaluated in humans 435 
[69]. The rate of protein digestion and therefore nitrogen incorporation in the plasma was higher 436 
with UHT than pasteurized and microfiltered milks. 437 
In summary, the effect of processing on milk proteins is often studied from a nutritional point of 438 
view. However, processing also has major implications on the bioaccessibility (i.e., release of 439 
peptides in the intestinal lumen) of milk proteins, which can affect their bioactive properties in 440 
humans. This stresses the importance of evaluating milk proteins in the final food product in 441 
which they will be incorporated in order to properly assess their potential health enhancing 442 
properties. 443 
11. Conclusions 444 
Several reports link the ingestion of milk proteins with the maintenance of a favorable health 445 
status. While demonstration of the occurrence of milk protein-derived peptide sequences in the 446 
GIT tract of humans has been established in a small number of instances, some questions remain 447 
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on the potential physiological role of these peptides in humans. For instance, very little to no 448 
information is available in terms of their stability, bioavailability and efficacy in humans. This 449 
constitutes a major gap in knowledge to allow a better understanding on the role of milk protein-450 
derived peptides in human health. Technological advances have been made in terms of peptide 451 
identification. These have allowed more accurate detection of peptide sequences within human 452 
biological fluids and tissues. However, the scientific evidence for the biological relevance of 453 
these peptides in humans is still lacking. The reasons for this may arise from the lack of 454 
knowledge on the mechanism of action involved, the low potency and low bioavailability of the 455 
milk protein-derived peptides and also the lack of knowledge on the time span (acute vs. chronic) 456 
for their in vivo activity. Despite the lack of clear evidence for the role of milk proteins in human 457 
health, selected bioactive properties such as muscle protein synthesis, insulinotropic and 458 
hypotensive activity appear to be consistently observed in human intervention studies. An urgent 459 
need exists for the development of integrated research platforms involving interdisciplinary skills 460 
to address the role and mechanism of action of milk protein-derived peptides in humans. 461 
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Table 1. Summary of the human intervention studies assessing the health enhancing properties of milk proteins. 
 
Table 2. Peptide sequences detected in the gastrointestinal tract of humans following the ingestion of bovine milk 
and dairy products and their associated in vitro bioactive properties. 
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Table 1 
Bioactivity Test sample Study design
1
 Biological outcome Reference 
Satiety WPC  Obese ♂ subjects (n=26) 
 65 g/day meal preload 
 Duration: 12 weeks 
 Appetite: -44%  
 Calories intake: -51% 
 anthropometric changes: body 
weight (-10%), BMI (-19%) 
and waist circumference (-41%) 
 body composition: body fat 
mass (-9%) and lean muscle 
mass (+9%) 
[122] 
 WPC80  Overweight and obese adults subjects 
(n=19) 
 Treatment: WPC80 
 Dose: 56 g protein/day meal preload 
 Duration: 23 weeks 
 Weight: -1.8 kg 
 Fat mass: -2.3 kg  
 Waist circumference: -2.4 cm  
 Fasting ghrelin: -13.6%  
[9] 
 Skimmed milk, 
WP and CN 
 Overweight adolescents (n=173) 
 Treatments (A): skimmed milk, (B): 
WP (C): CN and (D): water 
 Dose: 30 g/day  
 Duration: 12 weeks 
 Lean mass: increased in all 
groups 
 Fat mass: increased in all 
groups, except in (D) 
 Leptin: +30 and +15% in (C) 
and (B), respectively 
[72] 
 Skimmed milk, 
WP and CN 
 Overweight adolescents (n=203) 
 Treatments (A): Skimmed milk, (B): 
WP (C): CN and (D): water 
 Dose: 35 g/day  
 Duration: 12 weeks 
 BMI, BMI-for-age Z-scores: 
increased in groups (A), (B) 
and (C) 
 Weight: increased in groups 
(A), (B) and (C) 
[6] 
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 -La, CN, whey 
or WPC80 in a 
custard-style 
breakfast 
 Healthy adults (n=24) 
 Appetite assessment over180 min post-
breakfast 
 Dose: 10/55/35 (normal) or 25/55/20 
(high) energy% protein/carbohydrate/fat 
 -40% appetite at 180 min with 
-La 
 -20% food intake at lunch -La 
 No effect with CN, whey and 
WPC80 
[130] 
 WPC, CMP, -Lg 
and colostrum 
WPC  
 Lean ♂ (n=18) 
 Treatments (A): WPC, (B): CMP (C): 
-Lg and (D): colostrum WPC 
 Dose: 25 g preload 90 min before lunch 
 Greater feeling of subjective 
fullness with (C) 
 No reduction in food intake at 
lunch with (B), (C) and (D) 
compared to (A) 
[111] 
 WPC  Healthy young ♂ adults (n=16)  
 Treatment: ad libitum pizza meal vs. 
control (water) 
 Dose: 10-40 g 
 Subjective appetite: not affected 
by WP 
 Food intake: reduced in all WP 
groups with doses  20 g 
[1] 
 WPI, whey 
without CMP and 
CMP isolate  
 Healthy adults (n=20) 
 Treatments (A): WPI, (B): whey 
without CMP and (C): CMP 
 Dose: 25 g preload 75 min before lunch 
 Pre-meal subjective satiety: 
higher in all groups 
 (C) group of ♀: +33% CCK 
concentration 30 min after 
lunch and lower compensatory 
food intake on the study day (-
1.7 MJ) 
[21] 
 CMP isolate, WPI 
with low and high 
CMP  
 Healthy ♀ subjects (n=22) 
 Treatments (A): CMP, (B): WPI low 
CMP and (C): WPI high CMP 
 Dose: 60 g preload 120 min before 
lunch 
 Food intake: > -15% with (B) 
and (C) compared to (A) 
 Appetite suppression and food 
intake: no effect of CMP 
[27] 
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Hypotensive WPC80  Young normotensive and stage 1 pre-
hypertensive adults (n=71) 
 Dose: 28 g/day  
 Duration: 6 weeks 
 Pre-hypertensive group: DBP (-
8.6 mm Hg) and SBP (-8.0 mm 
Hg) 
 Normotensive group: No effect 
of WPC80 
[42] 
 WPI and CN  Overweight and obese subjects (n=89) 
 Treatments (A): CN and (B): WP 
 Dose: 54 g/day 
 Duration: 12 weeks 
 SBP: -5 mm Hg for both (A) 
and (B) 
 DBP: 5 mm Hg for both (A) 
and (B) 
 AI: -14% for (B) and no 
modification for (A) 
[102] 
 WPI and CN  Post-menopausal overweight ♀ (n=20) 
 Dose: 45 g/day 
 Duration: 3 weeks 
 No effect on AI, SBP and DBP [103] 
 WP and CN  Obese ♀ (n=33) 
 Treatments (A): WP, (B): CN and (C): 
carbohydrate control 
 Dose: 30 g/day and resistance exercise  
 Duration 4 weeks 
 SBP: -7 mm Hg for (A) and -6 
mm Hg (B) 
 DBP: no effect for (A) and (B) 
 AI: -34% for (A) and-31% for 
(B) 
 brachial-ankle pulse wave 
velocity: -4 cm s
-1
 for (A) and 
(B) 
[40] 
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 WP  Obese adolescents (12-15 y, n=193) 
 Treatments (A): skimmed milk, (B): 
WP, (C): CN and (D): water 
 Dose: 35 g/day 
 Duration: 12 weeks 
 DBP: -1.8 and -2.2 mm Hg for 
(C) and (D), respectively 
 SBP: no changes in all groups 
 Arterial stiffness: no changes in 
all groups 
[5] 
Antimicrobial Human 
recombinant LF  
 In tube fed long term patients (n=30) 
 Treatments (A): LF and (B): placebo 
control 
 Dose: LF (3 g) solution by gastrostomy 
administration 
 Duration: 56 days 
 Diarrhoea: 44% patients from 
(A) vs. 92% in (B) 
 No significant difference in the 
rate of infection by C. difficile 
in (A) and (B) 
[70] 
 Bovine LF  Patients (n=150) infected with H. pylori 
 Treatments (A): 
clarithromycin/tinidazole/rabeprazole+2
00 mg LF, (B): 
clarithromycin/tinidazole/rabeprazole 
for 7 days or (C): (B) for 10 days 
Duration: 7-10 days 
 H. pylori eradication: 92, 71 
and 70% in groups (A), (B) and 
(C), respectively 
[34] 
 Bovine LF  Patients (n=389) infected with H. pylori 
 Treatments (A): resomeprazole 
clarithromycin/tinidazole, (B): 200 mg 
LF or (C): (A)+200 mg LF 
 Duration: 7 days 
 H. pylori eradication: 77, 73 
and 90% in groups (A), (B) and 
(C), respectively 
[33] 
 Bovine LF  Patients (n=133) infected with H. pylori 
 Treatments (A): esomeprazole/ 
clarithromycin/amoxycillin or (B): 
(A)+200 mg LF 
 Duration: 7 days 
 H. pylori eradication: 80.3 and 
78.1% in groups (A) and (B), 
respectively 
 No significant difference 
between groups (A) and (B) 
[140] 
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 Human 
recombinant LF 
 Healthy subjects (n=6) infected with H. 
pylori 
 1 g LF 
 No clearance of H. pylori 
infection 
[101] 
 Human 
recombinant LF 
 Healthy subjects (n=9) infected with H. 
pylori 
 5 g LF daily  
 Duration: 5-14 days 
 No clearance of H. pylori 
infection 
[48] 
 Bovine LF  preterm VLBW neonates (n=472) 
 Treatments (A): LF, (B): (A) + 
Lactobacillus rhamnosus GG or (C): 
placebo 
 Dose: 100 mg/day LF 
 Duration: 6 weeks 
 Fungal colonisation: no 
difference between treatments 
 Invasive fungal infection: 0.7, 
2.0 and 7.7% in groups (A), (B) 
and (C), respectively 
 Rate colonization-infection: 
3.7, 12 and 41.9% in groups 
(A), (B) and (C), respectively 
[82] 
 Bovine LF  VLBW neonates (n=743) 
 Treatments (A): LF, (B): (A)+ 
Lactobacillus rhamnosus GG or (C): 
control 
 Dose: 100 mg/day LF 
 Duration: until age day 30 
 Incidence of NEC: 2.0, 0 and 
5.4% in groups (A), (B) and 
(C), respectively 
[80] 
Anti-
inflammatory 
WPI and CN   Obese non diabetic subjects (n=11) 
 Treatments: high fat meal with (A): 
WPI, (B): CN, (C): cod or (D): gluten 
  Dose: 45 g protein 
 Reduction of post-prandial low 
grade inflammation 
(CCL5/RANTES and MCP-1): 
in all group and particularly in 
(A) 
[53] 
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 WPI and CN  Overweight and obese subjects (n=89) 
 Dose: 54 g/day 
 Duration 12 weeks 
 No modification in 
inflammatory markers 
[102] 
 WPI and CN  Post-menopausal overweight women 
(n=20) 
 Dose: 45 g/day 
 Duration: 3 weeks 
 No effect on inflammatory 
markers, i.e., C-reactive protein 
(CRP), IL-6 and tumour 
necrosis factor (TNF)-α 
[103] 
Anticancer Bovine LF  Patients with adenomatous colorectal 
polyps (n=104) 
 Dose: 1.5 or 3 g/day 
 Duration: 12 months 
 Polyp growth: no significant 
effect overall 
 subjects  63 y, 3 g LF: 
retardation of polyp growth 
being more marked in ♀ than 
♂. 
[67] 
 Bovine LF  Colorectal cancer patients in 
chemotherapy (n=30) 
 Dose: 250 mg/day 
 Duration: 3 months 
 No effect of LF 
supplementation 
 Symptoms of colorectal cancer 
(e.g., anaemia): improved 
 Anti-inflammatory & 
immunomodulatory effect: 
increased. 
 Side-effects related to 
chemotherapy (liver and kidney 
toxicity and mucositis): 
alleviated 
[87] 
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 HAMLET  Patients with skin papillomas (n=40 & 
34) 
 Treatments (A): HAMLET and (B): 
placebo 
 Dose: 0.7 mM HAMLET topical 
application on each lesion  
 Duration: 3 weeks 
 Reduction of lesions: -75% in 
(A) 
 Time to resolution: 2.4 vs. 9.9 
months in (A) and (B), 
respectively 
[47] 
 HAMLET  Patients with bladder cancer (n=9) 
 Dose: daily bladder instillation of 
HAMLET 5  25 mg mL-1 
 Duration: 5 days 
 Shedding of tumour cells in the 
urine increased from 10
4
 to 2.9 
× 10
5
 cells mL
-1
 post treatment 
 Tumour cell apoptosis post 
treatment 
 Tumour size reduced: -50 % 
post treatment 
 Tumour surface atrophy post 
treatment 
[92] 
Antioxidant  WPI  Healthy ♂ (n=28) 
 Treatments (A): resistance training + 
WPI, (B): resistance training + placebo 
or (C): control 
 Dose: ~110 g/day 
 Duration: 6 weeks 
 Plasma total antioxidant 
capacity: +4% in group (A) 
compared to baseline 
 Plasma GSH: +12% in group 
(A) compared to baseline 
[119] 
 WP  Healthy ♂ (n=27) 
 Treatments (A): resistance training + 
WP, (B): resistance training + soy or 
(C): resistance training 
 Dose: 33 g/day formulated in bars 
 Duration: 9 weeks 
 Plasma antioxidant status: no 
effect in (A); decreased in (B) 
and (C) 
[18] 
 Cys-rich WPI  Patients with non-alcoholic  Plasma total antioxidant [26] 
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steatohepatitis (n=38) 
 Treatment: Cys-rich WPI 
 Dose: 20 g/day 
 Duration: 12 weeks 
capacity: +61% compared to 
baseline 
 Plasma GSH: +28% compared 
to baseline 
Glucoregulatory WP, CN  Type 2 diabetes subjects (n=12) 
 Fat rich meal (100 g butter + 45 g 
carbohydrate) + Treatments (A): CN, 
(B): WP, (C): cod or (D): gluten 
 Dose: 45 g 
 Insulin, glucagon, GLP-1, and 
GIP levels: no differences 
between groups  
 Blood glucose: significantly 
lower for (B) 
[91] 
 WP  Type 2 diabetes patients (n=8) 
 Treatments: high carbohydrate meal 
with (A): WP preload, (B): WP, (C): no 
WP 
 Dose: 55 g 
 Insulin and incretin levels: (A) 
and (B) > (C) 
 Glycaemia: (A) and (B) < (C), 
363.7, 406.3 and 734.9 mmol 
min
-1
 L
-1
, respectively 
[78] 
 WP  Type 2 diabetes subjects (n=14) 
 Treatments: high carbohydrate breakfast 
and lunch with (A): WP or (B): lean 
ham 
 Dose: 27.6 g 
 Insulin: (A) > (B), +31 and 
+57% after breakfast and lunch, 
respectively 
 Glycaemia: (A) < (B) -21 % 
 GIP: (A) > (B) 
 GLP-1: no difference between 
(A) and (B) 
[44] 
 WP  Type 2 diabetes subjects (n=15) 
 Treatments: high carbohydrate breakfast 
with (A): WP preload or (B): water 
 Dose: 50 g 
 Insulin: (A) > (B), +96%  
 Glycaemia: (A) < (B), -28 % 
 Intact and total GLP-1: (A) > 
(B), +141 and 298%, 
respectively 
[57] 
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 WPC  (1) Healthy young ♂ adults (n=16) and 
(2) healthy young ♂ and ♀ adults 
(n=21) 
 Treatments: ad libitum pizza meal (1) or 
preset pizza meal (2) with WP preload 
vs. control (water) 
 Dose: 10-40 g (1) and 5- 40 g (2) 
 Insulin levels: reduced in all 
WP groups with doses  10 g. 
  Glycaemia: reduced in all WP 
groups with doses  10 g 
[1] 
Muscle protein 
synthesis 
WP and CN  Healthy elderly ♂ (>70 y, n=72) 
 Treatments (A): WP and (B): micellar 
CN with or without resistance exercise. 
 Dose: 20 g 
 MPS: +65 and +60% higher in 
(A) than in (B) with and 
without resistance exercise, 
respectively 
[20] 
 WP and CN  Obese elderly subjects (n=12) 
 Treatments (A): WP and (B): CN in 
caloric restriction diets (1200 kcal/day) 
 Dose: 7 g (WP) and 14 g (CN) 
 Duration: 8 weeks 
 Muscle protein FSR: higher in 
(A) than (B) 
 Lean mass tissue: no difference 
in (A) and (B) 
 Fat loss: +30% higher in (A) 
than (B) 
[29] 
 WP and CN  Healthy elderly subjects (n=24) 
 Treatments (A): WP and (B): CN before 
or after heavy resistance exercise and 
(C): placebo control 
 Dose: 7 g (WP) and 14 g (CN) 
 FSR: no difference in (A) and 
(B) post exercise 
 MPS: no difference in (A) and 
(B) post exercise 
[35] 
 WP and CN  Healthy subjects (n=23) 
 Treatments (A): WP and (B): CN and 
(C): placebo control after resistance 
exercise 
 Dose: 20 g 
 amino acid balance: (A) and (B) 
> (C) with no difference 
between (A) and (B) 
[125] 
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 WP and CN  Healthy young subjects (n=16) 
 Treatments (A): CN, (B): WP and (C): 
control followed by resistance exercise 
 Dose: 30-43 g 
 MPS: higher in (A) and (B) 
than in (C) 
[114] 
 CN  Healthy young ♂ (n=18) 
 Treatments (A): CN, (B): WP 
hydrolysate and (C): soy protein isolate 
followed by resistance exercise  
 Dose: 21-22 g 
 MPS: significant increase after 
exercise in (B) and (C) but not 
(A) 
[124] 
1
No duration was indicated for acute studies.
 
AI: augmentation index;
 -La: -lactalbumin; -Lg: -lactoglobulin; BMI: body mass index; CCK: cholecystokinin; CCL5/RANTES: 
CC chemokine ligand-5 regulated on activation in normal T cell expressed and secreted; CMP: caseinomacropeptide; CN: casein; 
CRP: C-reactive protein; DBP: diastolic blood pressure; FSR: fractional synthesis rate; GLP-1: glucagon-like peptide 1; GIP: glucose-
dependent insulinotropic polypeptide; GSH: glutathione; (HAMLET: human -La made lethal to tumors; LF: lactoferrin; MCP-1: 
monocyte chemotactic protein-1; MPS: myofibriallar protein synthesis; NEC: necrotizing enterocolitis; SBP: systolic blood pressure; 
TNF-α: tumour necrosis factor-α; VLBW: very low birth weight; WPC: whey protein concentrate; WPI: whey protein isolate; ♂: 
male; ♀: female. 
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Table 2 
Parent 
protein
1
 
Fragment Peptide sequence
2
 Reference Reported in vitro bioactivity 
-CN 6-14 LNVPGEIVE [15] ACE inhibitor 
 7-14 NVPGEIVE [15] ACE inhibitor 
 47-52 DKIHPF [15] ACE-inhibitor 
 59-66 VYPFPGPI [15] ACE inhibitor, antiamnesic 
 59-67 VYPFPGPIP [15] ACE inhibitor, antiamnesic 
 59-68 VYPFPGPIPN [15] ACE-inhibitor 
 59-69 VYPFPGPIPNS [15] ACE-inhibitor 
 59-72 VYPFPGPIHNSLPQ [15] ACE-inhibitor 
 60-65 YPFPGP [15] opioid 
 60-66 YPFPGPI (-casomorphin-7) [15] opioid agonist, ACE-inhibitor, immunomodulator 
 60-67 YPFPGPIP [15] opioid agonist, ACE inhibitor 
 60-68 YPFPGPIPN [15] ACE and DPP-IV inhibitor 
 62-68 FPGPIPN [15] DPP-IV inhibitor 
 63-68 PGPIPN [15] immunomodulator 
 70-77 LPQNIPPL [15] DPP-IV inhibitor 
 71-77 PQNIPPL [15] DPP-IV inhibitor 
 73-82 NIPPLTQTPV [15] ACE inhibitor 
 74-82 IPPLTQTPV [15] DPP-IV inhibitor 
 75-82 PPLTQTPV [15] ACE inhibitor 
 80-90 TPVVVPPFLQP [15] ACE inhibitor 
 108-113 EMPFPK [15] hypotensive 
 130-140 VENLHLPLPLL [15] anticancer 
 131-138 ENLHLPLP [15] ACE inhibitor 
 132-138 NLHLPLP [15] ACE inhibitor 
 132-140 NLHLPLPLL [15] anticancer 
 133-138 LHLPLP [15] ACE inhibitor 
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 133-139 LHLPLPL [15] ACE inhibitor 
 134-139 HLPLPL [15] antiamnesic  
 135-139 LPLPL [15] DPP-IV inhibitor 
 168-175 SKVLPVPQ [15] hypotensive 
 170-176 VLPVPQK [15] antioxidant 
 191-201 LLYQEPVLGPV [15] immunostimulator (f 191-193) 
 192-206 LYQEPVLGPVRGPFPIL [15] immunomodulator, ACE-inhibitor (f 193-202) 
 192-207 LYQEPVLGPVRGPFPI [15] immunomodulator ACE-inhibitor (f 193-202) 
 192-208 LYQEPVLGPVRGPFPII [15] immunomodulator, ACE-inhibitor (f 193-202) 
 193-199 YQEPVLG [15] immunomodulator, ACE-inhibitor (f 193-202) 
 193-201 YQEPVLGPV [15] ACE-inhibitor (f 193-198) 
 193-205 YQEPVLGPVRGPF [15] immunomodulator, ACE-inhibitor (f 193-202) 
 193-206 YQEPVLGPVRGPFP [15] immunomodulator, ACE-inhibitor (f 193-202) 
 193-207 YQEPVLGPVRGPFPI [15] immunomodulator, ACE-inhibitor (f 193-202) 
 13-23 VESLS(P)S(P)S(P)EESIT [85] mineral binding 
 60-63 YPFP (bovine -casomorphin-4) [120] opioid 
 60-66 YPFPGPI (bovine -casomorphin-7) [120] opioid, ACE inhibitor 
s1-CN 143-149 AYFYPEL [25] ACE inhibitor 
 144-149 YFYPEL [25] ACE inhibitor, antioxidant 
-CN 106-116 MAIPPKKNQDK [25] platelet inhibitor 
 106-169 caseinomacropeptide [75] immunomodulatory 
1
CN: casein 
2
Peptide sequence with the one letter amino acid code; S(P) indicates phosphorylated serine residues. 
3
Bioactivity determined from Boutrou, Gaudichon, Dupont, Jardin, Airinei, Marsset-Baglieri et al. [15], Nongonierma and FitzGerald 
[98] and the BIOPEP database [86]; ACE: angiotensin converting enzyme; DPP-IV: dipeptidyl peptidase IV. 
 
 
